CircFAT1 Promotes the Proliferation and Invasion of Malignant Melanoma through miR375-SLC7A11 Signal Axis

Author:

Lu Tao12ORCID,Yang Danyang1,Li Xiaoli1

Affiliation:

1. Department of Dermatology, The Second Affiliated Hospital of Xi’an Jiaotong University, 157 Xiwu Road, Xi’an, 710004, China

2. Clinical Laboratory Center of Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Shaoxing, China

Abstract

Background: Circular RNA, as a member of noncoding RNA, plays an important role in the occurrence, development and metastasis of tumor cells. So far, the correlation between circular RNA and malignant melanoma remains obscure. Methods: RNA expression of circFAT1 and miR-375 in malignant melanoma (MM) tissues and cell lines was detected by RT-PCR. The proliferation, cloning, migration and invasion of SK-Mel-28 and A375 cells were assessed using CCK-8 test, clone formation and Transwell assay, respectively. CircRNA immunoprecipitation was used to validate the relationship between circFAT1 and miR-375. The binding between circFAT1 and miR-375, as well as SLC7A11 and miR-375 were verified by luciferase assay. Results: In our study,the circFAT1 was significantly overexpressed in the MM tissue than melanocytic nevi. Conversely, the expression of miR-375 in MM tissue was lower than in melanocytic nevi tissue. The underexpression of circFAT1 with siRNA plasmids significantly suppressed the proliferation, invasion and clone formation of MM cell line. Mechanistically, circFAT1 positively regulates the expression level of SLC7A11 by sponging miR-375. The promotive effects of circFAT1 on the proliferation and invasion ability of MM cells were reversed by the upregulation of miR-375. Conclusion: circFAT1 promotes the proliferation, invasion and clone formation of malignant melanoma cells by improving the expression level of SLC7A11 via sponging miR-375.

Funder

Zhejiang Medical Science and Technology Program

Publisher

Bentham Science Publishers Ltd.

Subject

Cancer Research,Pharmacology,Molecular Medicine

Reference21 articles.

1. Hanniford D.; Ulloa-Morales A.; Karz A.; Berzoti-Coelho M.G.; Moubarak R.S.; Sánchez-Sendra B.; Kloetgen A.; Davalos V.; Imig J.; Wu P.; Vasudevaraja V.; Argibay D.; Lilja K.; Tabaglio T.; Monteagudo C.; Guccione E.; Tsirigos A.; Osman I.; Aifantis I.; Hernando E.; Epigenetic silencing of CDR1as drives IGF2BP3-mediated melanoma invasion and metastasis. Cancer Cell 2020,37(1),55-70.e15

2. Law M.H.; Bishop D.T.; Lee J.E.; Brossard M.; Martin N.G.; Moses E.K.; Song F.; Barrett J.H.; Kumar R.; Easton D.F.; Pharoah P.D.P.; Swerdlow A.J.; Kypreou K.P.; Taylor J.C.; Harland M.; Randerson-Moor J.; Akslen L.A.; Andresen P.A.; Avril M.F.; Azizi E.; Scarrà G.B.; Brown K.M.; Dȩbniak, T.; Duffy, D.L.; Elder, D.E.; Fang, S.; Friedman, E.; Galan, P.; Ghiorzo, P.; Gillanders, E.M.; Goldstein, A.M.; Gruis, N.A.; Hansson, J.; Helsing, P.; Hočevar, M.; Höiom, V.; Ingvar, C.; Kanetsky, P.A.; Chen, W.V.; Landi, M.T.; Lang, J.; Lathrop, G.M.; Lubiński, J.; Mackie, R.M.; Mann, G.J.; Molven, A.; Montgomery, G.W.; Novaković S.; Olsson, H.; Puig, S.; Puig-Butille, J.A.; Qureshi, A.A.; Radford-Smith, G.L.; van der Stoep, N.; van Doorn, R.; Whiteman, D.C.; Craig, J.E.; Schadendorf, D.; Simms, L.A.; Burdon, K.P.; Nyholt, D.R.; Pooley, K.A.; Orr, N.; Stratigos, A.J.; Cust, A.E.; Ward, S.V.; Hayward, N.K.; Han, J.; Schulze, H.J.; Dunning, A.M.; Bishop, J.A.N.; Demenais, F.; Amos, C.I.; MacGregor, S.; Iles, M.M. Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. Nat Genet 2015,47(9),987-995

3. Smithy J.W.; Shoushtari A.N.; Adjuvant PD-1 blockade in resected melanoma: Is preventing recurrence enough? Cancer Discov 2022,12(3),599-601

4. McCulloch J.A.; Davar D.; Rodrigues R.R.; Badger J.H.; Fang J.R.; Cole A.M.; Balaji A.K.; Vetizou M.; Prescott S.M.; Fernandes M.R.; Costa R.G.F.; Yuan W.; Salcedo R.; Bahadiroglu E.; Roy S.; DeBlasio R.N.; Morrison R.M.; Chauvin J.M.; Ding Q.; Zidi B.; Lowin A.; Chakka S.; Gao W.; Pagliano O.; Ernst S.J.; Rose A.; Newman N.K.; Morgun A.; Zarour H.M.; Trinchieri G.; Dzutsev A.K.; Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat Med 2022,28(3),545-556

5. Lee K.A.; Thomas A.M.; Bolte L.A.; Björk J.R.; de Ruijter L.K.; Armanini F.; Asnicar F.; Blanco-Miguez A.; Board R.; Calbet-Llopart N.; Derosa L.; Dhomen N.; Brooks K.; Harland M.; Harries M.; Leeming E.R.; Lorigan P.; Manghi P.; Marais R.; Newton-Bishop J.; Nezi L.; Pinto F.; Potrony M.; Puig S.; Serra-Bellver P.; Shaw H.M.; Tamburini S.; Valpione S.; Vijay A.; Waldron L.; Zitvogel L.; Zolfo M.; de Vries E.G.E.; Nathan P.; Fehrmann R.S.N.; Bataille V.; Hospers G.A.P.; Spector T.D.; Weersma R.K.; Segata N.; Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nat Med 2022,28(3),535-544

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3